MedTrace Logo

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

NCT07527325 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-04-22

No results posted yet for this study

Summary

This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

Fianlimab

Given IV

DRUG

Cemiplimab

Given IV

Sponsors & Collaborators

  • UC Cancer Consortium

    collaborator UNKNOWN

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Warren Chow, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2029-02-01
Completion
2030-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07527325 on ClinicalTrials.gov